Devyser Diagnostics AB (publ) (STO:DVYSR)

Market Cap	2.16B
Revenue (ttm)	235.10M
Net Income (ttm)	-45.70M
Shares Out	16.65M
EPS (ttm)	-2.76
PE Ratio	n/a
Forward PE	95.12
Dividend	n/a
Ex-Dividend Date	n/a

Volume	81,542
Average Volume	29,315
Open	131.80
Previous Close	132.00
Day's Range	128.20 - 131.80
52-Week Range	83.30 - 159.60
Beta	0.75
RSI	35.87
Earnings Date	Nov 5, 2025

About Devyser Diagnostics AB

Devyser Diagnostics AB (publ) engages in the development, manufacture, and sale of diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. The company offers products in the areas of post-transplantation; thalassemia; breast, colorectal, and ovarian cancer; non-invasive fetal RHD screening prenatal testing, hereditary, cystic fibrosis, cardiovascular, male infertility, and rapid aneuploidy analys...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 121
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: DVYSR

Financial Performance

In 2024, Devyser Diagnostics AB's revenue was 216.90 million, an increase of 28.12% compared to the previous year's 169.30 million. Losses were -61.50 million, 14.7% more than in 2023.